Skip to Main Content Menu Search Site
3d rendering red blood cells in vein

Targeted EPO: Safely Normalizing Oxygen Delivery in a Broad Range of Disease Conditions

First-in-class safe engineered fusion protein addresses life-threatening and limiting low-oxygen conditions in a large patient population, and is commercialized by General Biologics

Want to join us?

The General Biologics team is looking for investors and clinical collaborators to take the next steps toward patients in need.


Synthetic Biology

Technology Development Team
Jeffrey Way Pam Silver
Key Features
  • Protein therapy to treat lack of oxygen in patients with a range of diseases, including COPD, cystic fibrosis, severe COVID-19, and anemias, such as those in kidney failure
  • Creative use of protein engineering technology enables conversion of a potent, yet potentially harmful, into a safe, much broader applicable therapy
  • Targeted erythropoietin (EPO) is a first-in-class fusion protein therapeutic that simultaneously binds to two surface proteins exclusively on red blood cell precursors.
Close menu